Navigation Links
Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France

100 Percent Purified Seawater Helps Users Breathe Freely

KENILWORTH, N.J., March 3 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the launch of AFRIN(R) PureSea(TM) Hydrating Nasal Rinse, the only nasal rinse product entirely made of 100 percent purified sea water. Available in the cold/allergy aisle at retailers nationwide, AFRIN PureSea is clinically proven to cleanse nasal and sinus passages of mucus, pollutants, and irritants so users can breathe freely.

To view the Multimedia News Release, go to:

"Nasal rinsing is a simple technique to cleanse nasal and sinus passages while helping you to breathe freely," said Mary Jo DiMilia, M.D., an internist at Mount Sinai Medical Center in New York. "AFRIN PureSea is a new and convenient way to clean nasal passages, because it requires no mixing, minimal cleanup, and stays sterile even after the product is used."

The sea water in AFRIN PureSea is taken from the Bay of Saint-Malo in France, home to some of the most powerful tides in the world. The strong currents renew the composition of the water, oxygenating it and replenishing its mineral content. A gentle and effective nasal rinse, AFRIN PureSea is non-medicated, can be used daily and comes ready to use with a specially designed applicator that fits the shape of the nostrils.

"With consumers becoming more proactive about their health, Schering-Plough recognized the need for a convenient nasal irrigation product that is all-natural and easy to use at home," said Dr. John O'Mullane, group vice president, research and development, Schering-Plough Consumer Health Care. "The composition of the purified sea water in AFRIN PureSea is very similar to that of the human body, striking the right balance of salt, minerals, and elements to effectively rinse nasal and sinus passages with minimal discomfort or stinging."

AFRIN PureSea Nasal Rinse is available in three forms of delivery -- Medium Stream, Gentle Mist, and Ultra-Gentle Mist -- and can be found at most drug stores, mass retailers, and grocery stores nationwide. Both the Medium Stream and Gentle Mist are designed for use in adults and children ages 2 and older, and the Ultra-Gentle Mist is designed for use in children 6 months and older.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough, an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for AFRIN PureSea. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. "Risk Factors" in Schering-Plough's 2008 10-K, filed February 27, 2009.

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
4. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
8. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
9. Video: Keppra XR(TM) Approved in the U.S.
10. Video: Fortune 1000 Executives: New President Must Fix Education Gap
11. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
Post Your Comments:
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):